Business Description
Galera Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US36338D1081
Share Class Description:
GRTX: Ordinary SharesDescription
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.61 | |||||
| Equity-to-Asset | -5.02 | |||||
| Debt-to-Equity | -0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 24.6 | |||||
| 3-Year FCF Growth Rate | 25.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.73 | |||||
| 9-Day RSI | 64.49 | |||||
| 14-Day RSI | 58.74 | |||||
| 6-1 Month Momentum % | -16.36 | |||||
| 12-1 Month Momentum % | -93.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.36 | |||||
| Quick Ratio | 4.36 | |||||
| Cash Ratio | 3.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.6 | |||||
| Shareholder Yield % | -269.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -136.8 | |||||
| ROIC % | -663.62 | |||||
| ROC (Joel Greenblatt) % | -4650.54 | |||||
| ROCE % | -150.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.12 | |||||
| EV-to-EBITDA | 0.12 | |||||
| EV-to-Forward-Revenue | 11.33 | |||||
| EV-to-FCF | 0.13 | |||||
| Earnings Yield (Greenblatt) % | 833.33 | |||||
| FCF Yield % | -443.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galera Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.34 | ||
| Beta | 2.51 | ||
| Volatility % | 133.89 | ||
| 14-Day RSI | 58.74 | ||
| 14-Day ATR ($) | 0.024171 | ||
| 20-Day SMA ($) | 0.17042 | ||
| 12-1 Month Momentum % | -93.35 | ||
| 52-Week Range ($) | 0.0853 - 3.59 | ||
| Shares Outstanding (Mil) | 54.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galera Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galera Therapeutics Inc Frequently Asked Questions
What is Galera Therapeutics Inc(GRTX)'s stock price today?
The current price of GRTX is $0.19. The 52 week high of GRTX is $3.59 and 52 week low is $0.09.
When is next earnings date of Galera Therapeutics Inc(GRTX)?
The next earnings date of Galera Therapeutics Inc(GRTX) is 2024-05-10 Est..
Does Galera Therapeutics Inc(GRTX) pay dividends? If so, how much?
Galera Therapeutics Inc(GRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers